Clinical advances in endocrine and metabolic disease in 2015

doi:10.3969/j.issn.1004-583X.2016.02.007

Abstract

Abstract: In 2015, development in the field of endocrine metabolism is rapid and colorful.Not only a lot of important guidelines have updated or issued, but also highlights in clinical research harvests much, covering the obesity, diabetes mellitus, thyroid disease, parathyroid disease, adrenal gland and gonad diseases, and others.The authors review and summarize the major progresses.

Key words: obesity, diabetes mellitus, thyroid diseases, parathyroid diseases, adrenal gland diseases, gonads

CLC Number:

Wang Mian, Zhang Lihui, Su Shenou. Clinical advances in endocrine and metabolic disease in 2015[J]. Clinical Focus, 2016, 31(2): 162-167.

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2016.02.007

https://huicui.hebmu.edu.cn/EN/Y2016/V31/I2/162

References

[1] World Health Organization. Obesity and overweight. WHO fact sheet N°311 [EB/OL]. Geneva: WHO, 2015. www.who.int/mediacentre/factsheets/fs311/en/(last accessed November 30, 2015).
[2] World Health Organization. World Health Statistics 2015[EB/OL]. Geneva:WHO, 2015, pp101-111.www.who.int/gho/publications/world_health_statistics/2015/en/(last accessed November 30, 2015).
[3] Kelly T, Yang W, Chen CS, et al. Global burden of obesity in 2005 and projections to 2030[J]. Int J Obes (Lond),2008,32(9): 1431-1437.
[4] Hou X, Lu J, Weng J, et al. Impact of waist circumference and body mass index on risk of cardiometabolic disorder and cardiovascular disease in Chinese adults: a national diabetes and metabolic disorders survey[J]. PLoS One, 2013, 8(3):e57319.
[5] Tian Y, Wu H. Prevalence of obesity among students aged 6 to 12 in China: a meta-analysis[J]. Food Nutr Res, 2015,17(59):25747.
[6] Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an endocrine society clinical practice guideline[J]. J Clin Endocrinol Metab,2015, 100(2): 342-362.
[7] Yumuk V, Tsigos C, Fried M, et al. European Guidelines for Obesity Management in Adults[J]. Obes Facts,2015, 8(6):402-424.
[8] Toplak H, Woodward E, Yumuk V, et al. 2014 EASO Position Statement on the Use of Anti-Obesity Drugs[J]. Obes Facts, 2015, 8(3):166-174.
[9] Stegenga H, Haines A, Jones K,et al.Identification, assessment, and management of overweight and obesity: summary of updated NICE guidance[J]. BMJ,2014, 349:g6608.
[10] Rao G, Powell-Wiley TM, Ancheta I, et al. Identification of obesity and cardiovascular risk in ethnically and racially diverse populations: a scientific statement from the American Heart Association[J]. Circulation,2015, 132(5): 457-472.
[11] Practice Committee of the American Society for Reproductive Medicine. Obesity and reproduction: a committee opinion[J]. Fertil Steril,2015, 104(5): 1116-1126.
[12] 中华医学会糖尿病学分会. 中国血糖监测临床应用指南(2015年版)[J].中华糖尿病杂志,2015, 7(10): 603-613.
[13] 陈莉明. 见微知著,引领未来解读2015中国血糖监测临床应用指南[J]. 中华糖尿病杂志, 2015, 7(10): 593-596.
[14] American Diabetes Association. Standards of medical care in diabetes— 2015[J]. Diabetes Care,2015, 38 (Suppl 1):S1-S93.
[15] Handelsman Y, Bloomgarden ZT, Grunberger G, et al. American association of clinical endocrinologists and american college of endocrinology-clinical practice guidelines for developing a diabetes mellitus comprehensive care plan-2015[J]. Endocr Pract, 2015, 21(Suppl 1):1-87.
[16] Garber AJ, Abrahamson MJ, Barzilay JI, et al. Aace/Ace comprehensive diabetes management algorithm 2015[J]. Endocr Pract, 2015, 21(4): 438-447.
[17] Fox CS, Golden SH, Anderson C, et al. Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: a scientific statement from the American Heart Association and the American Diabetes Association[J]. Circulation,2015, 132(8): 691-718.
[18] Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes[J]. Diabetes Care, 2015, 38(1):140-149.
[19] 中华医学会糖尿病学分会微血管并发症学组. 糖尿病肾病防治专家共识(2014年版)[J]. 中华糖尿病杂志,2014, 6(11): 792-801.
[20] Bakker K, Apelqvist J, Lipsky BA, et al. The 2015 IWGDF guidance documents on prevention and management of foot problems in diabetes: development of an evidence-based global consensus[J]. Diabetes Metab Res Rev,2015 Sep 27. [Epub ahead of print]
[21] The IWGDF Working Group on Foot Infection. IWGDF guidance on the diagnosis and management of foot infections in persons with diabetes[EB/OL].[2015 06 06]. http://www. iwgdf.org/files/ 2015 / website_infection.pdf.
[22] 许樟荣. 《国际糖尿病足工作组关于糖尿病足感染的诊断与处理指南》解读[EB/OL]. 中华糖尿病杂志, 2015,7(7): 403-404.
[23] Internal Clinical Guidelines team. Diabetic Foot Problems: Prevention and Management. London: National Institute for Health and Care Excellence (UK)[S]. 2015 Aug.
[24] Lavery LA, Davis KE, Berriman SJ, et al. WHS Guidelines Update: Diabetic Foot Ulcer Treatment Guidelines[J]. Wound Repair Regen, 2015 Dec 9. [Epub ahead of print]
[25] Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes[J]. N Engl J Med,2015, 373(22): 2117-2128.
[26] Zinman B, Inzucchi SE, Lachin JM, et al. Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME)[J]. Cardiovasc Diabetol, 2014, 13: 102.
[27] Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes[J]. N Engl J Med, 2015, 373(3): 232-242.
[28] Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome[J]. N Engl J Med,2015, 373(23): 2247-2257.
[29] Hayward RA, Reaven PD, Wiitala WL, et al. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes[J]. N Engl J Med,2015, 372(23): 2197-2206.
[30] An Y, Zhang P, Wang J, et al. Cardiovascular and all-cause mortality over a 23-year period among Chinese with newly diagnosed diabetes in the Da Qing IGT and Diabetes Study[J]. Diabetes Care, 2015, 38(7):1365-1371.
[31] Unger RH, Scherer PE, Holland WL. Dichotomous roles of leptin and adiponectin as enforcers against lipotoxicity during feast and famine[J]. Mol Biol Cell, 2013, 24(19): 3011-3015.
[32] Xia JY, Holland WL, Kusminski CM, et al. Targeted induction of ceramide degradation leads to improved systemic metabolism and reduced hepatic steatosis[J]. Cell Metab,2015, 22(2):266-278.
[33] Kajimura S, Spiegelman BM, Seale P, et al. Brown and Beige fat: physiological roles beyond heat generation[J].Cell Metab,2015, 22(4): 546-559.
[34] Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer[J]. Thyroid, 2016, 26(1): 1-133.
[35] Francis GL, Waguespack SG, Bauer AJ, et al. Management guidelines for children with thyroid nodules and differentiated thyroid cancer[J]. Thyroid,2015, 25(7): 716-759.
[36] Bollerslev J, Rejnmark L, Marcocci C, et al. European Society of Endocrinology Clinical Guideline: treatment of chronic hypoparathyroidism in adults[J]. Eur J Endocrinol, 2015, 173(2):G1-G20.
[37] Nieman LK, Biller BM, Findling JW, et al. Treatment of Cushing's syndrome: an endocrine society clinical practice guideline[J]. J Clin Endocrinol Metab,2015, 100(8):2807-2831.
[38] 中华医学会内分泌学分会性腺学组. 特发性低促性腺激素性性腺功能减退症诊治专家共识[J]. 中华内科杂志,2015, 54(8):739-744.
[39] Boehm U, Bouloux PM, Dattani MT, et al. Expert consensus document: European Consensus Statement on congenital hypogonadotropic hypogonadism-pathogenesis, diagnosis and treatment[J]. Nat Rev Endocrinol,2015, 11(9): 547-564.